BioCryst Pharma (BCRX) Tops Q1 EPS by 4c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.17 --0%
EPS Growth %: +6.7%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +6.7%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $92.76 million versus the consensus estimate of $85.82 million.
GUIDANCE:
BioCryst Pharma sees FY2024 revenue of $390-400 million, versus the consensus of $395.1 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- JPMorgan Reinstates Dauch Corporation (DCH) at Neutral
- RxSight cuts 2026 sales outlook, citing competitive headwinds
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
